<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02675244</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 08-1078-0010</org_study_id>
    <secondary_id>2U01HL088942-07</secondary_id>
    <nct_id>NCT02675244</nct_id>
  </id_info>
  <brief_title>Evaluating the Benefit of Concurrent Tricuspid Valve Repair During Mitral Surgery</brief_title>
  <official_title>Evaluating the Benefit of Concurrent Tricuspid Valve Repair During Mitral Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Society for Thoracic and Cardiovascular Surgery</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Deutsches Zentrum f√ºr Herz-Kreislauf-Forschung (DZHK)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the research is to determine whether repairing a tricuspid valve (TV) in&#xD;
      patients with mild to moderate tricuspid regurgitation (TR), at the time of planned mitral&#xD;
      valve surgery (MVS), would improve the heart health of those who receive it compared to those&#xD;
      who do not.&#xD;
&#xD;
      At this point, the medical community is split in their opinion on whether surgeons should&#xD;
      routinely repair mild to moderate TR in patients who are undergoing planned mitral valve&#xD;
      surgery, and this study will answer this question.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The tricuspid valve controls the flow of blood in your heart between the right ventricle and&#xD;
      the right atrium. TR is a condition where the valve does not close fully when it is supposed&#xD;
      to and blood can then leak back into the right atrium. When TR becomes severe, surgery is&#xD;
      usually performed to correct it. The purpose of the research is to determine whether&#xD;
      repairing a tricuspid valve in patients with mild to moderate TR, at the time of planned&#xD;
      mitral valve surgery, would improve the heart health of those who receive it compared to&#xD;
      those who do not. There are no new or &quot;experimental&quot; procedures being tested in this study:&#xD;
      both the mitral valve procedure and the tricuspid valve repair procedure are well established&#xD;
      surgeries and are regularly performed together in patients who have severe TR. The available&#xD;
      evidence addressing this issue is not definite: it is based on less rigorous methods of&#xD;
      investigation, and the results have been conflicting. The study being proposed here will use&#xD;
      rigorous scientific methods and should result in a very high level of certainty about what&#xD;
      surgical treatment is best for patients with your condition.&#xD;
&#xD;
      This study will enroll people scheduled for mitral valve surgery with mild to moderate&#xD;
      tricuspid regurgitation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 26, 2016</start_date>
  <completion_date type="Anticipated">April 19, 2024</completion_date>
  <primary_completion_date type="Actual">April 19, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Degree of TR Repair</measure>
    <time_frame>24 Months</time_frame>
    <description>Effectiveness of TR Repair assessed by a composite of death, reoperation for TR, or progression of TR from baseline by two grades or the presence of severe TR at 24 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACCE</measure>
    <time_frame>up to 24 Months</time_frame>
    <description>Major Adverse Cardiac and Cerebrovascular Events (MACCE) is defined as a non-weighted composite score comprised of the following components: Death, Stroke, and Serious heart failure events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA Classification</measure>
    <time_frame>up to 24 Months</time_frame>
    <description>Functional status will be assessed by the New York Heart Association (NYHA) Classification scale which ranges from 1 (no physical limitations) to 4 (severe limitation of physical activity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diuretic Use</measure>
    <time_frame>up to 24 Months</time_frame>
    <description>The diuretic requirements of patients will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six Minute Walk Test</measure>
    <time_frame>up to 24 Months</time_frame>
    <description>The total distance walked in six minutes will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of TR</measure>
    <time_frame>up to 24 Months</time_frame>
    <description>Degree of TR assessed by echocardiography, categorized according to American Society of Echocardiography guidelines as none/mild/moderate/severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Right Ventricular size</measure>
    <time_frame>up to 24 Months</time_frame>
    <description>Right ventricular (RV) size assessed by echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of RV function</measure>
    <time_frame>up to 24 Months</time_frame>
    <description>Degree of RV function assessed by echocardiography as normal, mildly impaired, moderately impaired, severely impaired.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak tricuspid annular velocity</measure>
    <time_frame>up to 24 Months</time_frame>
    <description>Degree of RV function assessed by peak tricuspid annular velocity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tricuspid annular peak systolic excursion (TAPSE)</measure>
    <time_frame>up to 24 Months</time_frame>
    <description>Degree of RV function assessed by TAPSE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Right ventricular fractional area change (RVFAC)</measure>
    <time_frame>up to 24 Months</time_frame>
    <description>Degree of RV function assessed by RVFAC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Artery Pressure</measure>
    <time_frame>up to 24 Months</time_frame>
    <description>Pulmonary artery pressure assessed by echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Right Ventricular Volume</measure>
    <time_frame>up to 24 Months</time_frame>
    <description>RV Volume as measured by transthoracic 3D echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-12</measure>
    <time_frame>up to 24 Months</time_frame>
    <description>Quality of Life assessed by SF-12. A measure of perceived health (health-related quality of life [QoL]) that describes the degree of general physical health status and mental health distress. Higher scores indicate higher levels of health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kansas City Cardiomyopathy Questionnaire (KCCQ)</measure>
    <time_frame>up to 24 Months</time_frame>
    <description>Quality of Life assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ). KCCQ is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life, in which higher scores reflect better health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQoL (EQ-5D)</measure>
    <time_frame>up to 24 Months</time_frame>
    <description>Quality of Life assessed by EuroQoL (EQ-5D) - a standardised instrument for use as a measure of health outcome. Higher scores indicate higher levels of health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>up to 60 Months</time_frame>
    <description>Incidence of participants alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Index Hospitalization</measure>
    <time_frame>average 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmission</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Incidence of readmissions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reoperations</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Incidence of reoperations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Economic Measures (Inpatient costs)</measure>
    <time_frame>up to 60 months</time_frame>
    <description>Inpatient costs will be measured through the collection of hospital billing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>60 months</time_frame>
    <description>Safety as measured by frequency of serious adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gait Speed Test</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Frailty will be assessed using the Gait Speed Test, which measures the speed of three 5 meter walks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">401</enrollment>
  <condition>Mild Tricuspid Regurgitation</condition>
  <condition>Moderate Tricuspid Regurgitation</condition>
  <condition>Tricuspid Regurgitation</condition>
  <arm_group>
    <arm_group_label>MVS Alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will undergo mitral valve surgery alone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MVS + TV Annuloplasty</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will undergo mitral valve surgery and tricuspid valve annuloplasty.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TV Annuloplasty</intervention_name>
    <description>TV Annuloplasty will be performed using standard surgical techniques</description>
    <arm_group_label>MVS + TV Annuloplasty</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MVS</intervention_name>
    <description>MVS will be performed using standard surgical techniques</description>
    <arm_group_label>MVS + TV Annuloplasty</arm_group_label>
    <arm_group_label>MVS Alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Undergoing MVS for degenerative MR* with (a) Moderate TR as determined by&#xD;
             transthoracic 2D echocardiography, or (b) Tricuspid annular dimension ‚â• 40 mm (index:&#xD;
             ‚â•21mm/M2 BSA) and none/trace or mild TR, determined by echocardiography.&#xD;
&#xD;
          -  Age ‚â• 18 years&#xD;
&#xD;
          -  Able to sign Informed Consent and Release of Medical Information forms&#xD;
&#xD;
               -  &quot;Degenerative mitral valve disease refers to a spectrum of conditions in which&#xD;
                  morphologic changes in the connective tissues of the mitral valve cause&#xD;
                  structural lesions . . ., such as chordal elongation, chordal rupture, leaflet&#xD;
                  tissue expansion, and annular dilation typically resulting in mitral&#xD;
                  regurgitation due to leaflet prolapse.&quot; This definition excludes rheumatic heart&#xD;
                  disease. (Anyanwu AC, Adams DH. (2007) Etiological classification of degenerative&#xD;
                  mitral valve disease: Barlow's disease and fibroelasticity deficiency. Semin&#xD;
                  Thorac Cardiovasc Surg; 19(2): 90-6).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Functional MR&#xD;
&#xD;
          -  Evidence of sub-optimal fluid management (e.g., lack of diuretics, weight in excess of&#xD;
             dry weight) in the opinion of the cardiology investigator&#xD;
&#xD;
          -  Structural / organic TV disease&#xD;
&#xD;
          -  Severe TV regurgitation as determined by preoperative transthoracic echocardiography&#xD;
             (TTE)&#xD;
&#xD;
          -  Implanted pacemaker or defibrillator, where the leads cross the TV from the right&#xD;
             atrium into the right ventricle&#xD;
&#xD;
          -  Concomitant cardiac surgery other than atrial fibrillation correction surgery (PVI,&#xD;
             Maze, LAA closure), closure of PFO or ASD, or CABG&#xD;
&#xD;
          -  Cardiogenic shock at the time of randomization&#xD;
&#xD;
          -  STEMI requiring intervention within 7 days prior to randomization&#xD;
&#xD;
          -  Evidence of cirrhosis or hepatic synthetic failure&#xD;
&#xD;
          -  Severe, irreversible pulmonary hypertension in the judgment of the investigator&#xD;
&#xD;
          -  Pregnancy at the time of randomization&#xD;
&#xD;
          -  Therapy with an investigational intervention at the time of screening, or plan to&#xD;
             enroll patient in additional investigational intervention study during participation&#xD;
             in this trial&#xD;
&#xD;
          -  Any concurrent disease with life expectancy &lt; 2 years&#xD;
&#xD;
          -  Unable or unwilling to provide informed consent&#xD;
&#xD;
          -  Unable or unwilling to comply with study follow up in the opinion of the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annetine C. Gelijns, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Weisel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Toronto General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine - Yale-New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520-8039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suburban Hospital</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Health</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health Services</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03766</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Einstein Heart Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook Hospital</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mission Hospital</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WakeMed Clinical Research Institute</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Research Institute</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health Systems</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Universit√© de Montr√©al</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H√¥pital du Sacr√©-C≈ìur de Montr√©al</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire de Cardiologie de Quebec (Hopital Laval)</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitares Herzzentrum Hamburg</name>
      <address>
        <city>Berlin</city>
        <state>Brandenburg</state>
        <zip>11353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig</name>
      <address>
        <city>Berlin</city>
        <state>Brandenburg</state>
        <zip>13347</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <state>Hesse-Nassau</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center G√∂ttingen</name>
      <address>
        <city>G√∂ttingen</city>
        <state>Lower Saxony</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Jena</name>
      <address>
        <city>Jena</city>
        <state>Thuringia</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HDZ NRW Bad Oeynhausen</name>
      <address>
        <city>Bad Oeynhausen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Center, University of Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>German Heart Center Munich</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 29, 2016</study_first_submitted>
  <study_first_submitted_qc>February 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2016</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Annetine Gelijns</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Tricuspid Valve Regurgitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

